NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Helfand M, Buckley D, Fleming C, et al. Screening for Intermediate Risk Factors for Coronary Heart Disease [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2009 Oct. (Evidence Syntheses, No. 73.)

Cover of Screening for Intermediate Risk Factors for Coronary Heart Disease

Screening for Intermediate Risk Factors for Coronary Heart Disease [Internet].

Show details

References

1.
Ferdinand KC. Coronary artery disease in minority racial and ethnic groups in the United States. Am J Cardiol. 2006 Jan 16;97(2A):12A–19A. [PubMed: 16442932]
2.
Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of the high blood cholesterol in adults (Adult panel III) JAMA. 2001;285:2486–2497. [PubMed: 11368702]
3.
Grundy SM, Cleeman JI, Bairey Merz CN, et al. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004;110:227–239. [PubMed: 15249516]
4.
Wilson PW, D’Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837–1847. [PubMed: 9603539]
5.
LLoyd-Jones DM, Nam B-H, D’Agostino S, et al. Parental Cardiovascular Disease as a Risk Factor for Cardiovascular Disease in Middle-aged Adults. A Prospective Study of Parents and Offspring. JAMA. 2004;291:2204–2211. [PubMed: 15138242]
6.
Najarian RM, Sullivan LM, Kannel LM, et al. Metabolic Syndrome Compared With Type 2 Diabetes Mellitus as a Risk Factor for Stroke: The Framingham Offspring Study. Arch Intern Med. 2006;166:106 – 111. [PubMed: 16401818]
7.
D’Agostino S, R B, Grundy SM, Sullivan LM, et al. Validation of the Framingham Coronary Heart Disease Prediction Scores. Results of a Multiple Ethnic Groups Investigation. JAMA. 2001;286:180–187. [PubMed: 11448281]
8.
Liu J, Hong Y, D’Agostino Sr RB, et al. Predictive Value for the Chinese Population of the Framingham CHD Risk Assessment Tool Compared With the Chinese Multi-provincial Cohort Study. JAMA. 2004;291:2591–2599. [PubMed: 15173150]
9.
McGill HC Jr, McMahan CA, Malcom GT, et al. Effects of serum lipoproteins and smoking on atherosclerosis in young men and women. The PDAY Research Group. Pathobiological Determinants of Atherosclerosis in Youth. Arterioscler Thromb Vasc Biol. 1997;17(1):95–106. [PubMed: 9012643]
10.
Smith SC Jr. Current and future directions of cardiovascular risk prediction. Am J Cardiol. 2006 Jan 16;97(2A):28A–32A. [PubMed: 16442934]
11.
Khot UN, Khot MB, Bajzer CT, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA. 2003;290:898–904. [PubMed: 12928466]
12.
Vasan RS, Sullivan LM, Wilson PWF, et al. Relative importance of borderline and elevated levels of coronary heart disease risk factors. Ann Intern Med. 2005;142:393–402. [PubMed: 15767617]
13.
Brotman DJ, Walker E, Lauer MS, et al. In search of fewer independent risk factors. Arch Intern Med. 2005;165(2):138–145. [PubMed: 15668358]
14.
Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342(12):836–843. [PubMed: 10733371]
15.
Grundy SM, Bazzarre T, Cleeman J. Prevention Conference V: beyond secondary prevention: identifying the high risk patient for primary prevention: medical office assessment. Circulation. 2000;101:e3–e11. [PubMed: 10618316]
16.
Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107(3):499–511. [PubMed: 12551878]
17.
Greenland P, Abrams J, Aurigemma GP, et al. Prevention Conference V: Beyond secondary prevention: identifying the high-risk patient for primary prevention: noninvasive tests of atherosclerotic burden: Writing Group III. Circulation. 2000;101(1):E16–22. [PubMed: 10618318]
18.
O’Rourke RA, Brundage BH, Froelicher VF, et al. American College of Cardiology/American Heart Association expert consensus document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease. Circulation. 2000;102:126–140. [PubMed: 10880426]
19.
National Cholesterol Education Program Expert Panel. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–3421. [PubMed: 12485966]
20.
Fryback DG, Thornbury JR. The efficacy of diagnostic imaging. Med Decis Making. 1991;11:88–94. [PubMed: 1907710]
21.
Harris RP, Helfand M, Woolf SH, et al. Current methods of the US Preventive Services Task Force. A review of the process. Am J Prev Med. 2001;30(3S):21–35. [PubMed: 11306229]
22.
Humphrey LL, Chan BK, Sox HC. Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Ann Intern Med. 2002;137:273–284. [PubMed: 12186518]
23.
Morris CD, Carson S. Routine vitamin supplementation to prevent cardiovascular disease: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2003;139:56–70. [PubMed: 12834320]
24.
Danesh J, Collins R, Appleby P, et al. Association of Fibrinogen, C-reactive protein, albumin or leukocyte count with Coronary Heart Disease: meta-analyses of prospective studies. JAMA. 1998;279:1477–1482. [PubMed: 9600484]
25.
Rumberger JA, Brundage BH, Rader DJ, et al. Electron beam computed tomographic coronary calcium scanning: a review and guidelines for use in asymptomatic persons. Mayo Clin Proc. 1999;74(3):243–252. [PubMed: 10089993]
26.
Pletcher MJ, Tice JA, Pignone M, et al. Using the coronary artery calcium score to predict coronary heart disease events: a systematic review and meta-analysis. Arch Intern Med. 2004;164(12):1285–1292. [PubMed: 15226161]
27.
Raggi P, Callister TQ, Cooil B, et al. Identification of patients at increased risk of first unheralded acute myocardial infarction by electron-beam computed tomography. Circulation. 2000;101(8):850–855. [PubMed: 10694523]
28.
Yang T, Doherty TM, Wong ND, et al. Alcohol consumption, coronary calcium, and coronary heart disease events. Am J Cardiol. 1999;84(7):802–806. [PubMed: 10513777]
29.
Raggi P, Cooil B, Callister TQ. Use of electron beam tomography data to develop models for prediction of hard coronary events. Am Heart J. 2001;141(3):375–382. [PubMed: 11231434]
30.
Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–634. [PMC free article: PMC2127453] [PubMed: 9310563]
31.
Duval S, Tweedie R. A nonparametric “trim and fill” method of accounting for publication bias in meta-analysis. J Am Stat Assoc. 2000;95(449):89–98.
32.
Caspard H, Chan AK, Walker AM. Compliance with a statin treatment in a usual-care setting: retrospective database analysis over 3 years after treatment initiation in health maintenance organization enrollees with dyslipidemia. Clin Ther. 2005;27(10):1639–1646. [PubMed: 16330301]
33.
National Center for Health Statistics. Current National Health and Nutrition Examination Survey (NHANES), 1999. [Accessed November 14, 2006]. Available at http://www​.cdc.gov/nchs​/about/major/nhanes/currentnhanes.htm.
34.
National Cholesterol Education Program. Adult Treatment Panel III (ATP III) Spreadsheet-based 10-year Risk Assessment Tool: Year 2000 version. [Accessed November 14, 2006]. Available at http://hp2010​.nhlbihin​.net/atpiii/RISK.EXE.
35.
Klein RJ, Schoenborn CA. Age Adjustment Using the 2000 Projected U.S. Population Statistical Notes No 20. CDC/National Center for Health Statistics; Jan, 2001 . 2000. [Accessed November 14, 2006]. Available at http://www​.cdc.gov/nchs​/data/statnt/statnt20.pdf. [PubMed: 11676466]
36.
Gordon T, Kannel WB. Predisposition to atherosclerosis in the head, heart, and legs. The Framingham study. JAMA. 1972;221(7):661–666. [PubMed: 4261853]
37.
Bovill EG, Bild DE, Heiss G, et al. White blood cell counts in persons aged 65 years or more from the Cardiovascular Health Study. Correlations with baseline clinical and demographic characteristics. Am J Epidemiol. 1996;143(11):1107–1115. [PubMed: 8633599]
38.
Friedman GD, Tekawa I, Grimm RH, et al. The leucocyte count: correlates and relationship to coronary risk factors: the CARDIA study. Int J Epidemiol. 1990;19(4):889–893. [PubMed: 2084017]
39.
Olivares R, Ducimetiere P, Claude JR. Monocyte count: a risk factor for coronary heart disease? Am J Epidemiol. 1993;137(1):49–53. [PubMed: 8434572]
40.
Zalokar J. Leukocyte count, smoking, and myocardial infarction. N Engl J Med. 1981;304(8):465–468. [PubMed: 7453772]
41.
Chambless LE, Folsom AR, Sharrett AR, et al. Coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC) study. J Clin Epidemiol. 2003;56(9):880–890. [PubMed: 14505774]
42.
Folsom AR, Wu KK, Rosamond WD, et al. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 1997;96(4):1102–1108. [PubMed: 9286936]
43.
Gillum RF, Ingram DD, Makuc DM. White blood cell count, coronary heart disease, and death: the NHANES I Epidemiologic Follow-up Study. Am Heart J. 1993;125(3):855–863. [PubMed: 8438715]
44.
Kannel WB, Anderson K, Wilson PW. White blood cell count and cardiovascular disease. Insights from the Framingham Study. JAMA. 1992;267(9):1253–1256. [PubMed: 1538564]
45.
Phillips AN, Neaton JD, Cook DG, et al. Leukocyte count and risk of major coronary heart disease events. Am J Epidemiol. 1992;136(1):59–70. [PubMed: 1415132]
46.
Prentice RL, Szatrowski TP, Fujikura T, et al. Leukocyte counts and coronary heart disease in a Japanese cohort. Am J Epidemiol. 1982;116(3):496–509. [PubMed: 7124717]
47.
Sweetnam PM, Thomas HF, Yarnell JW, et al. Total and differential leukocyte counts as predictors of ischemic heart disease: the Caerphilly and Speedwell studies. Am J Epidemiol. 1997;145(5):416–421. [PubMed: 9048515]
48.
Weijenberg MP, Feskens EJ, Kromhout D. White blood cell count and the risk of coronary heart disease and all-cause mortality in elderly men. Arterioscler Thromb Vasc Biol. 1996;16(4):499–503. [PubMed: 8624770]
49.
Wheeler JG, Mussolino ME, Gillum RF, et al. Associations between differential leucocyte count and incident coronary heart disease: 1764 incident cases from seven prospective studies of 30,374 individuals. Eur Heart J. 2004;25(15):1287–1292. [PubMed: 15288155]
50.
Manttari M, Manninen V, Koskinen P, et al. Leukocytes as a coronary risk factor in a dyslipidemic male population. Am Heart J. 1992;123(4 Pt 1):873–877. [PubMed: 1549995]
51.
Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2003;26( Suppl 1):S5–20. [PubMed: 12502614]
52.
Expert committee on the diagnosis and classification of diabetes mellitus: report of expert committee on the diagnosis and classification of the diabetes mellitus. Diabetes Care. 2004;27(Suppl 1):S5–S14. [PubMed: 14693921]
53.
Coutinho M, Gerstein HC, Wang Y, et al. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care. 1999;22(2):233–240. [PubMed: 10333939]
54.
Scheidt-Nave C, Barrett-Connor E, Wingard DL, et al. Sex differences in fasting glycemia as a risk factor for ischemic heart disease death. Am J Epidemiol. 1991;133(6):565–576. [PubMed: 2006643]
55.
Shaten BJ, Kuller LH, Neaton JD. Association between baseline risk factors, cigarette smoking, and CHD mortality after 10.5 years. MRFIT Research Group. Prev Med. 1991;20(5):655–659. [PubMed: 1758844]
56.
Schroll M, Hagerup L. Relationship of fasting blood glucose to prevalence of ECG abnormalities and 10 yr risk of mortality from cardiovascular diseases in men born in 1914: from the Glostrup population studies. J Chronic Dis. 1979;32(11–12):699–707. [PubMed: 315953]
57.
Ohlson LO, Svardsudd K, Welin L, et al. Fasting blood glucose and risk of coronary heart disease, stroke, and all-cause mortality: a 17-year follow-up study of men born in 1913. Diabet Med. 1986;3(1):33–37. [PubMed: 2951132]
58.
Pyorala K, Savolainen E, Kaukola S, et al. Plasma insulin as coronary heart disease risk factor: relationship to other risk factors and predictive value during 9 1/2-year follow-up of the Helsinki Policemen Study population. Acta Med Scand Suppl. 1985;701:38–52. [PubMed: 3907294]
59.
Yarnell JW, Pickering JE, Elwood PC, et al. Does non-diabetic hyperglycemia predict future IHD? Evidence from the Caerphilly and Speedwell studies. J Clin Epidemiol. 1994;47(4):383–388. [PubMed: 7730863]
60.
Antonicelli R, Gesuita R, Boemi M, et al. Random fasting hyperglycemia as cardiovascular risk factor in the elderly: a 6-year longitudinal study. Clin Cardiol. 2001;24(4):341–344. [PubMed: 11303705]
61.
Cohen HW, Hailpern SM, Alderman MH. Glucose-cholesterol interaction magnifies coronary heart disease risk for hypertensive patients. Hypertension. 2004;43(5):983–987. [PubMed: 15037563]
62.
Folsom AR, Szklo M, Stevens J, et al. A prospective study of coronary heart disease in relation to fasting insulin, glucose, and diabetes. The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care. 1997;20(6):935–942. [PubMed: 9167103]
63.
Meigs JB, Nathan DM, D’Agostino RB Sr, et al. Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care. 2002;25(10):1845–1850. [PubMed: 12351489]
64.
Qiao Q, Pyorala K, Pyorala M, et al. Two-hour glucose is a better risk predictor for incident coronary heart disease and cardiovascular mortality than fasting glucose. Eur Heart J. 2002;23(16):1267–1275. [PubMed: 12175663]
65.
Brown LJ, Brunelle JA, Kingman A. Periodontal status in the United States. J Dent Res. 1996;75:672–683. [PubMed: 8594091]
66.
Douglass CW, Jette AM, Fox CH, et al. Oral health status of the elderly in New England. J Gerontol. 1993;48:M39–M46. [PubMed: 8473693]
67.
Papapanou PN. Periodontal diseases: epidemiology. Ann Periodontol. 1996;1:1–36. [PubMed: 9118256]
68.
Ebersole JL, Machen RL, Steffen MJ, et al. Systemic acute-phase reactants, C-reactive protein and haptoglobin, in adult periodontitis. Clin Exp Immunol. 1997;107(2):347–352. [PMC free article: PMC1904587] [PubMed: 9030874]
69.
Slade GD, Offenbacher S, Beck JD, et al. Acute-phase inflammatory response to periodontal disease in the US population. J Dent Res. 2000;79(1):49–57. [PubMed: 10690660]
70.
Wu T, Trevisan M, Genco R, et al. Examination of the relation between periodontal health status and cardiovascular risk factors: serum total and high-density lipoprotein cholesterol, C-reactive protein, and plasma fibrinogen. Am J Epidemiol. 2000;151:273–282. [PubMed: 10670552]
71.
Ajwani S, Mattila KJ, Tilvis RS, et al. Periodontal disease and mortality in an aged population. Spec Care Dentist. 2003;23(4):125–130. [PubMed: 14765890]
72.
Beck J, Garcia R, Heiss G, et al. Periodontal disease and cardiovascular disease. J Periodontol. 1996;67(10 Suppl):1123–1137. [PubMed: 8910831]
73.
DeStefano F, Anda RF, Kahn HS, et al. Dental disease and risk of coronary heart disease and mortality. BMJ. 1993;306(6879):688–691. [PMC free article: PMC1677081] [PubMed: 8471920]
74.
Howell TH, Ridker PM, Ajani UA, et al. Periodontal disease and risk of subsequent cardiovascular disease in U.S. male physicians. J Am Coll Cardiol. 2001;37(2):445–450. [PubMed: 11216961]
75.
Hujoel PP, Drangsholt M, Spiekerman C, et al. Periodontal disease and coronary heart disease risk. JAMA. 2000;284(11):1406–1410. [PubMed: 10989403]
76.
Hung HC, Joshipura KJ, Colditz G, et al. The association between tooth loss and coronary heart disease in men and women. J Public Health Dent. 2004;64(4):209–215. [PubMed: 15562943]
77.
Morrison HI, Ellison LF, Taylor GW. Periodontal disease and risk of fatal coronary heart and cerebrovascular diseases. J Cardiovasc Risk. 1999;6(1):7–11. [PubMed: 10197286]
78.
Tuominen R, Reunanen A, Paunio M, et al. Oral health indicators poorly predict coronary heart disease deaths. J Dent Res. 2003;82(9):713–718. [PubMed: 12939356]
79.
Salonen JT, Salonen R, Seppanen K, et al. Interactions of serum copper, selenium, and low density lipoprotein cholesterol in atherogenesis. BMJ. 1991;302(6779):756–760. [PMC free article: PMC1669559] [PubMed: 2021765]
80.
Cao JJ, Thach C, Manolio TA, et al. C-reactive protein, carotid intima-media thickness, and incidence of ischemic stroke in the elderly: the Cardiovascular Health Study. Circulation. 2003;108(2):166–170. [PubMed: 12821545]
81.
Chambless LE, Folsom AR, Clegg LX, et al. Carotid wall thickness is predictive of incident clinical stroke: the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol. 2000;151(5):478–487. [PubMed: 10707916]
82.
Hollander M, Hak AE, Koudstaal PJ, et al. Comparison between measures of atherosclerosis and risk of stroke: the Rotterdam Study. Stroke. 2003;34(10):2367–2372. [PubMed: 12958327]
83.
Belcaro G, Nicolaides AN, Laurora G, et al. Ultrasound morphology classification of the arterial wall and cardiovascular events in a 6-year follow-up study. Arterioscler Thromb Vasc Biol. 1996;16(7):851–856. [PubMed: 8673559]
84.
Bots ML, Hoes AW, Koudstaal PJ, et al. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation. 1997;96(5):1432–1437. [PubMed: 9315528]
85.
Chambless LE, Heiss G, Folsom AR, et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987–1993. Am J Epidemiol. 1997;146(6):483–494. [PubMed: 9290509]
86.
O’Leary DH, Polak JF, Kronmal RA, et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med. 1999;340(1):14–22. [PubMed: 9878640]
87.
Van der Meer IM, Bots ML, Hofman A, et al. Predictive value of noninvasive measures of atherosclerosis for incident myocardial infarction: the Rotterdam Study. Circulation. 2004;109(9):1089–1094. [PubMed: 14993130]
88.
Budoff MJ, Georgiou D, Brody A, et al. Ultrafast computed tomography as a diagnostic modality in the detection of coronary artery disease: a multicenter study. Circulation. 1996;93(5):898–904. [PubMed: 8598080]
89.
Mautner SL, Mautner GC, Froehlich J, et al. Coronary artery disease: prediction with in vitro electron beam CT. Radiology. 1994;192(3):625–630. [PubMed: 8058925]
90.
Nallamothu BK, Saint S, Bielak LF, et al. Electron-beam computed tomography in the diagnosis of coronary artery disease: a meta-analysis. Arch Intern Med. 2001;161(6):833–838. [PubMed: 11268225]
91.
Arad Y, Spadaro LA, Goodman K, et al. Prediction of coronary events with electron beam computed tomography. J Am Coll Cardiol. 2000;36(4):1253–1260. [PubMed: 11028480]
92.
Wong ND, Hsu JC, Detrano RC, et al. Coronary artery calcium evaluation by electron beam computed tomography and its relation to new cardiovascular events. Am J Cardiol. 2000;86(5):495–498. [PubMed: 11009264]
93.
Arad Y, Goodman KJ, Roth M, et al. Coronary calcification, coronary disease risk factors, C-reactive protein, and atherosclerotic cardiovascular disease events: the St. Francis Heart Study. J Am Coll Cardiol. 2005;46(1):158–165. [PubMed: 15992651]
94.
Kondos GT, Hoff JA, Sevrukov A, et al. Electron-beam tomography coronary artery calcium and cardiac events: a 37-month follow-up of 5635 initially asymptomatic low- to intermediate-risk adults. Circulation. 2003;107(20):2571–2576. [PubMed: 12743005]
95.
Greenland P, LaBree L, Azen SP, et al. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA. 2004;291(2):210–215. [PubMed: 14722147]
96.
Vliegenthart R, Oudkerk M, Hofman A, et al. Coronary calcification improves cardiovascular risk prediction in the elderly. Circulation. 2005;112(4):572–577. [PubMed: 16009800]
97.
LaMonte MJ, FitzGerald SJ, Church TS, et al. Coronary artery calcium score and coronary heart disease events in a large cohort of asymptomatic men and women. Am J Epidemiol. 2005;162(5):421–429. [PubMed: 16076829]
98.
Taylor AJ, Bindeman J, Feuerstein I, et al. Coronary calcium independently predicts incident premature coronary heart disease over measured cardiovascular risk factors. mean three-year outcomes in the Prospective Army Coronary Calcium (PACC) Project. JACC. 2005;46:807–814. [PubMed: 16139129]
99.
Eikelboom JW, Lonn E, Genest J Jr, et al. Homocysteine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med. 1999;131(5):363–375. [PubMed: 10475890]
100.
McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol. 1969;56(1):111–128. [PMC free article: PMC2013581] [PubMed: 5792556]
101.
Wilcken DE, Wilcken B. The pathogenesis of coronary artery disease. A possible role for methionine metabolism. J Clin Invest. 1976;57(4):1079–1082. [PMC free article: PMC436752] [PubMed: 947949]
102.
Mudd SH, Skovby F, Levy HL, et al. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet. 1985;37(1):1–31. [PMC free article: PMC1684548] [PubMed: 3872065]
103.
Lentz SR, Sobey CG, Piegors DJ, et al. Vascular dysfunction in monkeys with diet-induced hyperhomocysteinemia. J Clin Invest. 1996;98(1):24–29. [PMC free article: PMC507396] [PubMed: 8690798]
104.
Yarnell JW, Sweetnam PM, Rumley A, et al. Lifestyle and hemostatic risk factors for ischemic heart disease: the Caerphilly Study. Arterioscler Thromb Vasc Biol. 2000;20(1):271–279. [PubMed: 10634829]
105.
Brattstrom L, Israelsson B, Norrving B, et al. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease. Effects of pyridoxine and folic acid treatment. Atherosclerosis. 1990;81(1):51–60. [PubMed: 2407253]
106.
Selhub J, Jacques PF, Wilson PW, et al. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA. 1993;270(22):2693–2698. [PubMed: 8133587]
107.
Ubbink JB, Vermaak WJ, van der Merwe A, et al. Vitamin B-12, vitamin B-6, and folate nutritional status in men with hyperhomocysteinemia. Am J Clin Nutr. 1993;57(1):47–53. [PubMed: 8416664]
108.
Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA. 2002;288(16):2015–2022. [PubMed: 12387654]
109.
Boushey CJ, Beresford SA, Omenn GS, et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA. 1995;274(13):1049–1057. [PubMed: 7563456]
110.
Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ. 2002 Nov 23;325(7374):1202. [PMC free article: PMC135491] [PubMed: 12446535]
111.
Ueland PM, Nygard O, Vollset SE, et al. The Hordaland Homocysteine Studies. Lipids. 2001;36(9) Suppl: S33 [PubMed: 11837990]
112.
Wilcken DE, Gupta VJ. Sulphr containing amino acids in chronic renal failure with particular reference to homocystine and cysteine-homocysteine mixed disulphide. Eur J Clin Invest. 1979;9(4):301–307. [PubMed: 118020]
113.
Albert CM, Ma J, Rifai N, et al. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation. 2002;105(22):2595–2599. [PubMed: 12045163]
114.
Alfthan G, Pekkanen J, Jauhiainen M, et al. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis. 1994;106(1):9–19. [PubMed: 8018111]
115.
Arnesen E, Refsum H, Bonaa KH, et al. Serum total homocysteine and coronary heart disease. Int J Epidemiol. 1995;24(4):704–709. [PubMed: 8550266]
116.
Blacher J, Benetos A, Kirzin JM, et al. Relation of plasma total homocysteine to cardiovascular mortality in a French population. Am J Cardiol. 2002;90(6):591–595. [PubMed: 12231082]
117.
Bots ML, Launer LJ, Lindemans J, et al. Homocysteine and short-term risk of myocardial infarction and stroke in the elderly: the Rotterdam Study. Arch Intern Med. 1999;159(1):38–44. [PubMed: 9892328]
118.
de Bree A, Verschuren WM, Blom HJ, et al. Coronary heart disease mortality, plasma homocysteine, and B-vitamins: a prospective study. Atherosclerosis. 2003;166(2):369–377. [PubMed: 12535751]
119.
Evans RW, Shaten BJ, Hempel JD, et al. Homocysteine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial. Arterioscler Thromb Vasc Biol. 1997;17(10):1947–1953. [PubMed: 9351358]
120.
Fallon UB, Ben-Shlomo Y, Elwood P, et al. Homocysteine and coronary heart disease in the Caerphilly cohort: a 10 year follow-up. Heart. 2001;85(2):153–158. [PMC free article: PMC1729619] [PubMed: 11156664]
121.
Folsom AR, Nieto FJ, McGovern PG, et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 1998;98(3):204–210. [PubMed: 9697819]
122.
Hoogeveen EK, Kostense PJ, Jakobs C, et al. Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes: 5-year follow-up of the Hoorn Study. Circulation. 2000;101(13):1506–1511. [PubMed: 10747342]
123.
Hultdin J, Thogersen AM, Jansson JH, et al. Elevated plasma homocysteine: cause or consequence of myocardial infarction? J Intern Med. 2004;256(6):491–498. [PubMed: 15554950]
124.
Knekt P, Alfthan G, Aromaa A, et al. Homocysteine and major coronary events: a prospective population study amongst women. J Intern Med. 2001;249(5):461–465. [PubMed: 11350570]
125.
Knekt P, Reunanen A, Alfthan G, et al. Hyperhomocystinemia: a risk factor or a consequence of coronary heart disease? Arch Intern Med. 2001;161(13):1589–1594. [PubMed: 11434790]
126.
Lind P, Hedblad B, Hultberg B, et al. Risk of myocardial infarction in relation to plasma levels of homocysteine and inflammation-sensitive proteins: a long-term nested case-control study. Angiology. 2003;54(4):401–410. [PubMed: 12934759]
127.
Ridker PM, Manson JE, Buring JE, et al. Homocysteine and risk of cardiovascular disease among postmenopausal women. JAMA. 1999;281(19):1817–1821. [PubMed: 10340369]
128.
Shai I, Stampfer MJ, Ma J, et al. Homocysteine as a risk factor for coronary heart diseases and its association with inflammatory biomarkers, lipids and dietary factors. Atherosclerosis. 2004;177(2):375–381. [PubMed: 15530913]
129.
Stampfer MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. JAMA. 1992;268(7):877–881. [PubMed: 1640615]
130.
Verhoef P, Hennekens CH, Allen RH, et al. Plasma total homocysteine and risk of angina pectoris with subsequent coronary artery bypass surgery. Am J Cardiol. 1997;79(6):799–801. [PubMed: 9070565]
131.
Voutilainen S, Lakka TA, Hamelahti P, et al. Plasma total homocysteine concentration and the risk of acute coronary events: the Kuopio Ischaemic Heart Disease Risk Factor Study. J Intern Med. 2000;248(3):217–222. [PubMed: 10971788]
132.
Wald NJ, Watt HC, Law MR, et al. Homocysteine and ischemic heart disease: results of a prospective study with implications regarding prevention. Arch Intern Med. 1998;158(8):862–867. [PubMed: 9570171]
133.
Whincup PH, Refsum H, Perry IJ, et al. Serum total homocysteine and coronary heart disease: prospective study in middle aged men. Heart. 1999;82(4):448–454. [PMC free article: PMC1760283] [PubMed: 10490559]
134.
Bostom AG, Silbershatz H, Rosenberg IH, et al. Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. Arch Intern Med. 1999;159(10):1077–1080. [PubMed: 10335684]
135.
Nurk E, Tell GS, Vollset SE, et al. Plasma total homocysteine and hospitalizations for cardiovascular disease: the Hordaland Homocysteine Study. Arch Intern Med. 2002;162(12):1374–1381. [PubMed: 12076236]
136.
Sacco RL, Anand K, Lee H-S, et al. Homocysteine and the risk of ischemic stroke in a triethnic cohort: the Northern Manhattan Study. Stroke. 2004;35(10):2263–2269. [PubMed: 15345803]
137.
Stehouwer CD, Weijenberg MP, van den Berg M, et al. Serum homocysteine and risk of coronary heart disease and cerebrovascular disease in elderly men: a 10-year follow-up. Arterioscler Thromb Vasc Biol. 1998;18(12):1895–1901. [PubMed: 9848881]
138.
Ubbink JB, Fehily AM, Pickering J, et al. Homocysteine and ischaemic heart disease in the Caerphilly cohort. Atherosclerosis. 1998;140(2):349–356. [PubMed: 9862278]
139.
Vollset SE, Refsum H, Tverdal A, et al. Plasma total homocysteine and cardiovascular and noncardiovascular mortality: the Hordaland Homocysteine Study. Am J Clin Nutr. 2001;74(1):130–136. [PubMed: 11451728]
140.
Voutilainen S, Virtanen JK, Rissanen TH, et al. Serum folate and homocysteine and the incidence of acute coronary events: the Kuopio Ischaemic Heart Disease Risk Factor Study. Am J Clin Nutr. 2004;80(2):317–323. [PubMed: 15277151]
141.
Zylberstein DE, Bengtsson C, Bjorkelund C, et al. Serum homocysteine in relation to mortality and morbidity from coronary heart disease: a 24-year follow-up of the population study of women in Gothenburg. Circulation. 2004;109(5):601–606. [PubMed: 14769681]
142.
Jacques PF, Bostom AG, Wilson PW, et al. Determinants of plasma total homocysteine concentration in the Framingham Offspring cohort. Am J Clin Nutr. 2001;73(3):613–621. [PubMed: 11237940]
143.
Nygard O, Vollset SE, Refsum H, et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA. 1995;274(19):1526–1533. [PubMed: 7474221]
144.
Jager A, Kostense PJ, Nijpels G, et al. Serum homocysteine levels are associated with the development of microalbuminuria: the Hoorn study. Arterioscler Thromb Vasc Biol. 2001;21(1):74–81. [PubMed: 11145936]
145.
Shlipak MG, Sarnak MJ, Katz R, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med. 2005;352(20):2049–2060. [PubMed: 15901858]
146.
Shlipak MG, Fried LF, Cushman M, et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA. 2005;293(14):1737–1745. [PubMed: 15827312]
147.
Berg K. A new serum type system in man - the Lp system. Acta Pathol Microbiol Scand. 1963;59:369–382. [PubMed: 14064818]
148.
McLean J. cDNA sequence of human apoliprotein is homologous to plasmainogen. Nature. 1987;300:132–137. [PubMed: 3670400]
149.
Boerwinkle E, Leffert CC, Lin J, et al. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest. 1992;90(1):52–60. [PMC free article: PMC443062] [PubMed: 1386087]
150.
Edelberg JM, Pizzo SV. Lipoprotein (a) in the regulation of fibrinolysis. J Atheroscler Thromb. 1995;2( Suppl 1):S5–7. [PubMed: 9225222]
151.
Fuster V. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med. 1992;326:242–250. [PubMed: 1727977]
152.
Miles LA, Fless GM, Levin EG, et al. A potential basis for the thrombotic risks associated with lipoprotein(a) Nature. 1989;339(6222):301–303. [PubMed: 2542796]
153.
Hoefler G, Harnoncourt F, Paschke E, et al. Lipoprotein Lp(a). A risk factor for myocardial infarction. Arteriosclerosis. 1988;8(4):398–401. [PubMed: 2969235]
154.
Kostner GM, Avogaro P, Cazzolato G, et al. Lipoprotein Lp(a) and the risk for myocardial infarction. Atherosclerosis. 1981;38(1–2):51–61. [PubMed: 7470205]
155.
Routi T, Ronnemaa T, Jokinen E, et al. Correlation of toddlers’ serum lipoprotein(a) concentration with parental values and grandparents’ coronary heart disease: the STRIP baby study. Acta Paediatrica. 1996;85(4):407–412. [PubMed: 8740296]
156.
Howard BV, Le NA, Belcher JD, et al. Concentrations of Lp(a) in black and white young adults: relations to risk factors for cardiovascular disease. Ann Epidemiol. 1994;4(5):341–350. [PubMed: 7981840]
157.
Wang W, Hu D, Lee ET, et al. Lipoprotein(a) in American Indians is low and not independently associated with cardiovascular disease. The Strong Heart Study. Ann Epidemiol. 2002;12(2):107–114. [PubMed: 11880218]
158.
Braeckman L, De Bacquer D, Rosseneu M, et al. Determinants of lipoprotein(a) levels in a middle-aged working population. Eur Heart J. 1996;17(12):1808–1813. [PubMed: 8960421]
159.
Chien KL, Lee YT, Sung FC, et al. Lipoprotein (a) level in the population in Taiwan: relationship to sociodemographic and atherosclerotic risk factors. Atherosclerosis. 1999;143(2):267–273. [PubMed: 10217355]
160.
Nago N, KK, Hiraoka J, et al. Lipoprotein(a) levels in the Japanese population: influence of age and sex, and relation to atherosclerotic risk factors. The Jichi Medical School Cohort Study. Am J Epidemiol. 1995;141(9):815–821. [PubMed: 7717357]
161.
Jenner JL, Ordovas JM, Lamon-Fava S, et al. Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels. The Framingham Offspring Study. Circulation. 1993;87(4):1135–1141. [PubMed: 8462142]
162.
Rosengren A, Wilhelmsen L, Eriksson E, et al. Lipoprotein (a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men. BMJ. 1990;301(6763):1248–1251. [PMC free article: PMC1664422] [PubMed: 2148699]
163.
Assmann G, Schulte H, von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol. 1996;77(14):1179–1184. [PubMed: 8651092]
164.
Bostom AG, Gagnon DR, Cupples LA, et al. A prospective investigation of elevated lipoprotein (a) detected by electrophoresis and cardiovascular disease in women. The Framingham Heart Study. Circulation. 1994;90(4):1688–1695. [PubMed: 7923652]
165.
Bostom AG, Cupples LA, Jenner JL, et al. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study. JAMA. 1996;276(7):544–548. [PubMed: 8709403]
166.
Cantin B, Despres JP, Lamarche B, et al. Association of fibrinogen and lipoprotein(a) as a coronary heart disease risk factor in men (The Quebec Cardiovascular Study) Am J Cardiol. 2002;89(6):662–666. [PubMed: 11897206]
167.
Cantin B, Gagnon F, Moorjani S, et al. Is lipoprotein(a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study. J Am Coll Cardiol. 1998;31(3):519–525. [PubMed: 9502629]
168.
Cantin B, Lamarche B, Despres JP, et al. Does correction of the Friedewald formula using lipoprotein(a) change our estimation of ischemic heart disease risk? The Quebec Cardiovascular Study. Atherosclerosis. 2002;163(2):261–267. [PubMed: 12052472]
169.
Cremer P, Nagel D, Labrot B, et al. Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Gottingen Risk Incidence and Prevalence Study (GRIPS) Eur J Clin Invest. 1994;24(7):444–453. [PubMed: 7957500]
170.
Cremer P, Nagel D, Mann H, et al. Ten-year follow-up results from the Goettingen Risk, Incidence and Prevalence Study (GRIPS). I. Risk factors for myocardial infarction in a cohort of 5790 men. Atherosclerosis. 1997;129(2):221–230. [PubMed: 9105565]
171.
Kronenberg F, Kronenberg MF, Kiechl S, et al. Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study. Circulation. 1999;100(11):1154–1160. [PubMed: 10484534]
172.
Luc G, Bard JM, Arveiler D, et al. Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study. Atherosclerosis. 2002;163(2):377–384. [PubMed: 12052486]
173.
Nguyen TT, Ellefson RD, Hodge DO, et al. Predictive value of electrophoretically detected lipoprotein(a) for coronary heart disease and cerebrovascular disease in a community-based cohort of 9936 men and women. Circulation. 1997;96(5):1390–1397. [PubMed: 9315522]
174.
Price JF, Lee AJ, Rumley A, et al. Lipoprotein (a) and development of intermittent claudication and major cardiovascular events in men and women: the Edinburgh Artery Study. Atherosclerosis. 2001;157(1):241–249. [PubMed: 11427227]
175.
Salomaa V, Rasi V, Kulathinal S, et al. Hemostatic factors as predictors of coronary events and total mortality: The FINRISK ’92 Hemostasis Study. Arterioscler Thromb Vasc Biol. 2002;22(2):353–358. [PubMed: 11834541]
176.
Seed M, Ayres KL, Humphries SE, et al. Lipoprotein (a) as a predictor of myocardial infarction in middle-aged men. Am J Med. 2001;110(1):22–27. [PubMed: 11152861]
177.
Sharrett AR, Ballantyne CM, Coady SA, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2001;104(10):1108–1113. [PubMed: 11535564]
178.
Von Eckardstein A, Schulte H, Cullen P, et al. Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk. J Am Coll Cardiol. 2001;37(2):434–439. [PubMed: 11216959]
179.
Suk Danik J, Rifai N, Buring JE, et al. Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women. JAMA. 2006;296(11):1363–1370. [PubMed: 16985228]
180.
Dahlen GH, Weinehall L, Stenlund H, et al. Lipoprotein(a) and cholesterol levels act synergistically and apolipoprotein A-I is protective for the incidence of primary acute myocardial infarction in middle-aged males. An incident case-control study from Sweden. J Intern Med. 1998;244(5):425–430. [PubMed: 9845859]
181.
Jauhiainen M, Koskinen P, Ehnholm C, et al. Lipoprotein (a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. Atherosclerosis. 1991;89(1):59–67. [PubMed: 1837713]
182.
Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA. 1993;270(18):2195–2199. [PubMed: 8411602]
183.
Schaefer EJ, Lamon-Fava S, Jenner JL, et al. Lipoprotein(a) levels and risk of coronary heart disease in men. The lipid Research Clinics Coronary Primary Prevention Trial. JAMA. 1994;271(13):999–1003. [PubMed: 8139085]
184.
Thogersen AM, Soderberg S, Jansson JH, et al. Interactions between fibrinolysis, lipoproteins and leptin related to a first myocardial infarction. Eur J Cardiovasc Prev Rehabil. 2004;11(1):33–40. [PubMed: 15167204]
185.
Wild SH, Fortmann SP, Marcovina SM. A prospective case-control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford Five-City Project participants. Arterioscler Thromb Vasc Biol. 1997;17(2):239–245. [PubMed: 9081676]
186.
Pischon T, Girman CJ, Sacks FM, et al. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation. 2005;112(22):3375–3383. [PubMed: 16316964]
187.
Craig WY, Neveux LM, Palomaki GE, et al. Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies. Clin Chem. 1998;44(11):2301–2306. [PubMed: 9799757]
188.
Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation. 2000;102(10):1082–1085. [PubMed: 10973834]
189.
Evans RW, Shpilberg O, Shaten BJ, et al. Prospective association of lipoprotein(a) concentrations and apo(a) size with coronary heart disease among men in the Multiple Risk Factor Intervention Trial. J Clin Epidemiol. 2001;54(1):51–57. [PubMed: 11165468]
190.
Marcovina S. Use a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lp(a) Clin Chem. 2000;46:1956–1967. [PubMed: 11106328]
191.
Kronenberg. Lipoprotein(a) in stored plasma samples and the ravages of time. Why epidemiological studies may fail. Arterioscler Thromb Vasc Biol. 1996;16:1568–1572. [PubMed: 8977463]
192.
Taddei-Peters W. Quantification of Lp(a) particles containing various apo(a) isofoms by a monoclonal anti-apo(a) sandwich enzyme immunoassay for Lp(a) Clin Chem. 1993;30:1382–1389. [PubMed: 7687203]
193.
Berg K, Dahlen G, Christophersen B, et al. Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study. Clin Genet. 1997;52(5):254–261. [PubMed: 9520115]
194.
Danik JS, Rifai N, Buring JE, et al. Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women. JAMA. 2006;296(11):1363–1370. [PubMed: 16985228]
195.
Tillett WS, Francis T Jr. Serological reactions in pneumonia with a nonprotein somatic fraction of pneumococcus. J Exp Med. 1930;52:561–585. [PMC free article: PMC2131884] [PubMed: 19869788]
196.
Pepys MB, Hirschfield GM. C-reactive protein: a critical update.[erratum appears in J Clin Invest. 2003 Jul;112(2):299] J Clin Invest. 2003;111(12):1805–1812. [PMC free article: PMC161431] [PubMed: 12813013]
197.
Lemieux I, Pascot A, Prud’homme D. Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol. 2001;21:961–967. [PubMed: 11397704]
198.
Miller M, Zhan M, Havas S. High Attributable Risk of Elevated C-Reactive Protein Level to Conventional Coronary Heart Disease Risk Factors. The Third National Health and Nutrition Examination Survey. Arch Intern Med. 2005;165:2063–2068. [PubMed: 16216995]
199.
Scirica BM, Morrow DA. Is C-reactive protein an innocent bystander or proatherogenic culprit? The Verdict Is Still Out. Circulation. 2006;113:2128–2151. [PubMed: 16651484]
200.
Hingorani AD, Shah T, Casas JP. Linking observational and genetic approaches to determine the role of C-reactive protein in heart disease risk. Eur. Heart J. 2006;27(11):1261 – 1263. [PubMed: 16684780]
201.
Kuller LH, Tracy RP, Shaten J, et al. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol. 1996;144(6):537–547. [PubMed: 8797513]
202.
Koenig W, Sund M, Frohlich M, et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation. 1999;99(2):237–242. [PubMed: 9892589]
203.
Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, Aspirin, and the Risk of Cardiovascular Disease in Apparently Healthy Men. N Engl J Med. 1997;336:973–979. [PubMed: 9077376]
204.
Danesh J, Whincup P, Walker M, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ. 2000;321(7255):199–204. [PMC free article: PMC27435] [PubMed: 10903648]
205.
Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350(14):1387–1397. [PubMed: 15070788]
206.
Blake GJ, Rifai N, Buring JE, et al. Blood pressure, C-reactive protein, and risk of future cardiovascular events. Circulation. 2003;108(24):2993–2999. [PubMed: 14638538]
207.
Koenig W, Lowel H, Baumert J, et al. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation. 2004;109(11):1349–1353. [PubMed: 15023871]
208.
Koenig W, Khuseyinova N, Lowel H, et al. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation. 2004;110(14):1903–1908. [PubMed: 15451783]
209.
Lawlor DA, Smith GD, Rumley A, et al. Associations of fibrinogen and C-reactive protein with prevalent and incident coronary heart disease are attenuated by adjustment for confounding factors. British Women’s Heart and Health Study. Thromb Haemost. 2005;93(5):955–963. [PubMed: 15886815]
210.
Lowe GD, Yarnell JW, Rumley A, et al. C-reactive protein, fibrin D-dimer, and incident ischemic heart disease in the Speedwell study: are inflammation and fibrin turnover linked in pathogenesis? Arterioscler Thromb Vasc Biol. 2001;21(4):603–610. [PubMed: 11304479]
211.
Lowe GD, Sweetnam PM, Yarnell JW, et al. C-reactive protein, fibrin D-dimer, and risk of ischemic heart disease: the Caerphilly and Speedwell studies. Arterioscler Thromb Vasc Biol. 2004;24(10):1957–1962. [PubMed: 15308549]
212.
Mendall MA, Strachan DP, Butland BK, et al. C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur Heart J. 2000;21(19):1584–1590. [PubMed: 10988010]
213.
Park R, Detrano R, Xiang M, et al. Combined use of computed tomography coronary calcium scores and C-reactive protein levels in predicting cardiovascular events in nondiabetic individuals. Circulation. 2002;106(16):2073–2077. [PubMed: 12379576]
214.
Pirro M, Bergeron J, Dagenais GR, et al. Age and duration of follow-up as modulators of the risk for ischemic heart disease associated with high plasma C-reactive protein levels in men. Arch Intern Med. 2001;161(20):2474–2480. [PubMed: 11700160]
215.
Ridker PM, Rifai N, Cook NR, et al. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA. 2005;294(3):326–333. [PubMed: 16030277]
216.
Ridker PM, Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation. 2004;109(16):1955–1959. [PubMed: 15051634]
217.
Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347(20):1557–1565. [PubMed: 12432042]
218.
St-Pierre AC, Cantin B, Bergeron J, et al. Inflammatory markers and long-term risk of ischemic heart disease in men A 13-year follow-up of the Quebec Cardiovascular Study. Atherosclerosis. 2005;182(2):315–321. [PubMed: 16159604]
219.
Wilson PWF, Nam B-H, Pencina; M, et al. C-Reactive Protein and Risk of Cardiovascular Disease in Men and Women From the Framingham Heart Study. Arch Intern Med. 2005;165:2473 – 2478. [PubMed: 16314543]
220.
Luc G, Bard JM, Juhan-Vague I, et al. C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME Study. Arterioscler Thromb Vasc Biol. 2003;23(7):1255–1261. [PubMed: 12775578]
221.
Pai JK, Pischon T, Ma J, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med. 2004;351(25):2599–2610. [PubMed: 15602020]
222.
Pradhan AD, Manson JE, Rossouw JE, et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women’s Health Initiative observational study. JAMA. 2002;288(8):980–987. [PubMed: 12190368]
223.
Ridker PM, Buring JE, Shih J, et al. Prospective Study of C-Reactive Protein and the Risk of Future Cardiovascular Events Among Apparently Healthy Women. Circulation. 1998;98:731–733. [PubMed: 9727541]
224.
Rifai N, Buring JE, Lee IM, et al. Is C-reactive protein specific for vascular disease in women? Ann Intern Med. 2002;136(7):529–533. [PubMed: 11926788]
225.
Van der Meer IM, de Maat MPM, Kiliaan AJ, et al. The value of C-reactive protein in cardiovascular risk prediction: the Rotterdam Study. Arch Intern Med. 2003;163(11):1323–1328. [PubMed: 12796068]
226.
Witherell HL, Smith KL, Friedman GD, et al. C-reactive protein, Helicobacter pylori, Chlamydia pneumoniae, cytomegalovirus and risk for myocardial infarction. Ann Epidemiol. 2003;13(3):170–177. [PubMed: 12604160]
227.
Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2004;109(7):837–842. [PubMed: 14757686]
228.
Folsom AR, Aleksic N, Catellier D, et al. C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk In Communities (ARIC) study. Am Heart J. 2002;144(2):233–238. [PubMed: 12177639]
229.
Moons KGM, Harrell FE. Sensitivity and specificity should be de-emphasized in diagnostic accuracy studies. Acad Radiol. 2003;10(6):670–672. [PubMed: 12809422]
230.
Pepe MS, Feng Z, Huang Y, et al. Integrating the predictiveness of a marker with its performance as a classifier. UW Biostatistics Working Paper Series. 2006. [Accessed November 14, 2006]. Working Paper 289 (June 1). Available at http://www​.bepress.com​/uwbiostat/paper289. [PMC free article: PMC2939738] [PubMed: 17982157]
231.
Pepe MS, Janes H, Longton G, et al. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol. 2004;159(9):882–890. [PubMed: 15105181]
232.
Cook NR, Buring JE, Ridker PM. The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med. 2006;145(1):21–29. [PubMed: 16818925]
233.
Hujoel PP, Drangsholt M, Spiekerman C, et al. Examining the link between coronary heart disease and the elimination of chronic dental infections. J Am Dent Assoc. 2001;132(7):883–889. [PubMed: 11480641]
234.
Desai MY, Nasir K, Braunstein JB, et al. Underlying risk factors incrementally add to the standard risk estimate in detecting subclinical atherosclerosis in low- and intermediate-risk middle-aged asymptomatic individuals. Am Heart J. 2004;148(5):871–877. [PubMed: 15523320]
235.
Michos ED, Nasir K, Braunstein JB, et al. Framingham risk equation underestimates subclinical atherosclerosis risk in asymptomatic women. Atherosclerosis. 2006;184(1):201–206. [PubMed: 15907856]
236.
Rumberger JA. Clinical use of coronary calcium scanning with computed tomography. Cardiol Clin. 2003;21(4):535–547. [PubMed: 14719567]
237.
Pignone M, Fowler-Brown A, Pletcher M, et al. Systematic Evidence Review Number 22. Rockville, MD: Agency for Healthcare Research & Quality; 2003. [Assessed June 2008]. Screening for Asymptomatic Coronary Artery Disease: A Systematic Review for the U.S. Preventive Services Task Force. Available at http://www​.ahrq.gov/downloads​/pub/prevent/pdfser/chdser.pdf.
238.
Wong N, Detrano RC, Diamond G. Does coronary artery screening by electron beam computed tomography motivate potentially beneficial lifestyle behaviors? Am J Cardiol. 1996;78:1220–1223. [PubMed: 8960578]
239.
O’Malley PG, Rupard EJ, Jones DL, et al. Does the diagnosis of coronary calcification with electron beam computed tomography motivate behavioral change in smokers? J Mil Med. 2002;167:211–214. [PubMed: 11901568]
240.
Lonn E, Yusuf S, Arnold MJ, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354(15):1629–1632. [PubMed: 16531613]
241.
Bonaa KH, Njolstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006;354(15):1578–1588. [PubMed: 16531614]
242.
Achenbach S, Ropers D, Pohle K, et al. Influence of lipid-lowering therapy on the progression of coronary artery calcification: a prospective evaluation. Circulation. 2002;106(9):1077–1082. [PubMed: 12196332]
243.
Arad Y, Spadaro LA, Roth M, et al. Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E: the St. Francis Heart Study randomized clinical trial. J Am Coll Cardiol. 2005;46(1):166–172. [PubMed: 15992652]
244.
Nicklas BJ, You T, Pahor M. Behavioural treatments for chronic systemic inflammation: effects of dietary weight loss and exercise training. Can Med. Assoc. J. 2005;172:1199 – 1209. [PMC free article: PMC557073] [PubMed: 15851714]
245.
Nissen SE, Tuzcu EM, P S, et al. Statin Therapy, LDL Cholesterol, C-Reactive Protein, and Coronary Artery Disease. N Engl J Med. 2005;352:29–38. [PubMed: 15635110]
246.
Raggi P, Shaw LJ, Berman DS, et al. Gender-based differences in the prognostic value of coronary calcification. J Womens Health. 2004;13(3):273–283. [PubMed: 15130256]
247.
Vliegenthart R, Oudkerk M, Song B, et al. Coronary calcification detected by electron-beam computed tomography and myocardial infarction. The Rotterdam Coronary Calcification Study. Eur Heart J. 2002;23(20):1596–1603. [PubMed: 12323159]
248.
Yoon HC, Goldin JG, Greaser LE 3rd, et al. Interscan variation in coronary artery calcium quantification in a large asymptomatic patient population. Am J Roentgenol. 2000;174(3):803–809. [PubMed: 10701629]
249.
Nelson JC, Kronmal RA, Carr JJ, et al. Measuring coronary calcium on CT images adjusted for attenuation differences. Radiology. 2005;235(2):403–414. [PubMed: 15858082]
250.
Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003;289(19):2534–2544. [PubMed: 12759325]
251.
U.S. Preventive Services Task Force. Screening for high blood pressure: recommendations and rationale. Am J Prev Med. 2003;25(2):159–164. [PubMed: 12880885]
252.
Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation. 1998;97(20):2007–2011. [PubMed: 9610529]
253.
Ford ES, Giles WH, Mokdad AH. The distribution of 10-Year risk for coronary heart disease among US adults: findings from the National Health and Nutrition Examination Survey III. J Am Coll Cardiol. 2004;43:1791–1796. [PubMed: 15145101]
254.
Carroll MD, Lacher DA, Sorlie PD, et al. Trends in serum lipids and lipoproteins of adults, 1960–2002. JAMA. 2005;294(14):1773–1781. [PubMed: 16219880]
255.
Cromwell J, Bartosch WJ, Fiore MC, et al. Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. Agency for Health Care Policy and Research. JAMA. 1997;278(21):1759–1766. [PubMed: 9388153]
256.
Fiore MC. US public health service clinical practice guideline: treating tobacco use and dependence. Respir Care. 2000;45(10):1200–1262. [PubMed: 11054899]
257.
Harris JR, Schauffler HH, Milstein A, et al. Expanding health insurance coverage for smoking cessation treatments: experience of the Pacific Business Group on Health. Am J Health Promot. 2001;15(5):350–356. [PubMed: 11502016]
258.
Chasan-Taber L, Selhub J, Rosenberg IH, et al. A prospective study of folate and vitamin B6 and risk of myocardial infarction in US physicians. J Am Coll Nutrition. 1996;15(2):136–143. [PubMed: 8778142]

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (1.6M)

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...